… Based on the clinical and laboratory features and lung pathological manifestations of
COVID-19 … for the severe COVID-19 through blockade of transforming growth factor-beta (TGF-β). …

… transforming growth factor-beta (TGF-β) in immune responses of the lungs. Furthermore, we
discuss their possible implications in severe COVID-19 … of convalescent COVID-19 patients. …

… of TGF-β pathways in the … TGF-β inhibitors in those patients recovered from COVID-19
to mitigate a possible development of pulmonary fibrosis and its consequences for post-COVID-19 …

… on the microvasculature in COVID-19. In addition, we explore the potential role of existing
TGF-β inhibitors for the prevention and treatment of COVID-19 associated microvascular …

… In severe COVID-19, serum levels of TGFβ peak during the first two … in a TGFβ-dependent
manner. Our data reveal that an untimely production of TGFβ is a hallmark of severe COVID-19 …

… Coronavirus disease 2019 (COVID-19) has rapidly spread … coronavirus (SARS-CoV),
Influenza A virus subtype H1N1 and most recently Middle East respiratory syndrome coronavirus (…

… with additional TGF-β (Fig. 3a). In summary, severely affected COVID-19 patients show a …
, which initially is controlled by IFNs, IL-2, and TGF-β, and later on predominantly by TGF-β. …

… Transforming growth factor β (TGF-β), a pleiotropic cytokine with potent regulatory and
inflammatory activity, which is important for balancing the immune response [22], was increased …

… COVID-19. Nevertheless, implications of this important study could include the monitoring
of plasma TGF-β levels in COVID-19 … use of TGF-β blockers in the treatment of COVID-19. …

… Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions …
severe COVID-19 infection. Rise in inflammatory markers like transforming growth factor β (TGF-β)…